Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


07.08.2017

1 Am J Obstet Gynecol
1 Br J Cancer
1 Cancer
1 Cancer Chemother Pharmacol
1 Clin Cancer Res
2 Gynecol Oncol
1 Lancet Oncol
2 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Obstet Gynecol

  1. STANHISER J, Chagin K, Jelovsek JE
    A Model to Predict Risk of Blood Transfusion After Gynecologic Surgery.
    Am J Obstet Gynecol. 2017 Jan 16. pii: S0002-9378(17)30104.
    PubMed     Text format     Abstract available


    Br J Cancer

  2. TABUNG FK, Huang T, Giovannucci EL, Smith-Warner SA, et al
    The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer

  3. EVERETT EN
    The evolving role of cytopathology in the era of neoadjuvant chemotherapy for the accurate pathologic diagnosis of epithelial ovarian cancer.
    Cancer. 2017 Jul 31. doi: 10.1002/cncy.21894.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  4. MENDIVIL AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, et al
    Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
    Cancer Chemother Pharmacol. 2017;80:405-410.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  5. WEIGELT B, Comino-Mendez I, de Bruijn I, Tian L, et al
    Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0544.2017.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  6. FLEMING ND, Coleman RL, Tung C, Westin SN, et al
    Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31177.
    PubMed     Text format     Abstract available

  7. CHOI C, Kim WY, Lee DH, Oh SS, et al
    Cytoreduction of bulky para-aortic lymphadenopathy from metastatic ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31173.
    PubMed     Text format    


    Lancet Oncol

  8. PUJADE-LAURAINE E, Ledermann JA, Selle F, Gebski V, et al
    Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Jul 25. pii: S1470-2045(17)30469.
    PubMed     Text format     Abstract available


    Oncol Rep

  9. ZHANG J, Liu L, Han S, Li Y, et al
    B7-H3 is related to tumor progression in ovarian cancer.
    Oncol Rep. 2017 Jul 31. doi: 10.3892/or.2017.5858.
    PubMed     Text format     Abstract available

  10. BAE JS, Lee J, Park Y, Park K, et al
    Attenuation of MUC4 potentiates the anticancer activity of auranofin via regulation of the Her2/Akt/FOXO3 pathway in ovarian cancer cells.
    Oncol Rep. 2017 Jul 28. doi: 10.3892/or.2017.5853.
    PubMed     Text format     Abstract available


    PLoS One

  11. LANDSKRON J, Kraggerud SM, Wik E, Dorum A, et al
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
    PLoS One. 2017;12:e0182030.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: